Blog

Dr Neil Fish joined Boyds in November 2021 as Vice President of Business Development, and has subsequently established the business development function, bringing in the required skills and best practise to support the development of new opportunities for Boyds. In his blog, Neil reflects on his first six months. My first six months at Boyds has been an exciting ride. If I reflect on where I was a year ago, I was actually a client of Boyds and was also

The latest data on Advanced Therapy clinical trials has been released by the Cell and Gene Therapy Catapult recently (March 2022), showing that the UK was delivering 12% of the total ATMP clinical trials globally1. There is continued steady growth from 2017 to 2021 with the latest full-year having 168 trials ongoing versus 154 in 2020. It is likely that Covid has played a part in the numbers, both preventing some trials from closing but also reducing the number of

World Cancer Day is held every year on 4 February to raise worldwide awareness and globally unite in the fight against cancer. The awareness day has created a positive movement globally, educating and paving the way to a world where millions of preventable cancer deaths are saved and access to treatment and care is available for all. This year, World Cancer Day, organised by the Union for International Cancer Control (UICC), campaigns the message ‘Close the care gap.’ Currently, millions of

The Code of Federal Regulations, specifically 21 CFR § 207.69, requires all domestic and foreign companies to have an official contact located in the US in order to act as the primary contact with the FDA and liaise between the FDA and the sponsor company for all communications. Specifically for non-US (foreign) entities, any company that wishes to register a new medicine or device with the FDA must appoint a US agent, as must foreign companies that wish to import

For Siobhan Gaynor, a love of science, and the workings of the body, medicine and the disease process, has underpinned a 30-year career in drug development. But earlier this year, this knowledge and experience informed the very toughest of personal decisions for Siobhan following her diagnosis of metastatic breast cancer. Siobhan Gaynor’s love of biology was inspired by a schoolteacher who had worked in industry herself, who highlighted the opportunities that lay ahead and helped to crystalise her passion and

Across the UK, and indeed the world, there is significant growth and clinical progress being made in the field of advanced therapy medicinal products (ATMPs). In this article, Ian Hollingsworth, Associate Director of Product Development at Boyds explores the changing landscape of ATMPs in the UK. ATMPs comprise of gene therapies, somatic cell therapies and tissue engineered products. This class of treatments offers the potential to address significant unmet medical needs for patients, offering the promise of treating diseases currently

Boyds’ Vice President of Regulatory Affairs, Julie Warner, has co-edited an article in the October issue of the TOPRA journal, Regulatory Rapporteur, which focuses on medical technologies. The following article, A brave new world for medical technologies, was published in Regulatory Rapporteur, Volume 18, issue 10, October 2021. By Julie Warner, Vice President of Regulatory Affairs, Alan Boyd Consultants Ltd, UK, and Steve Dew, Executive Director, Organon & Co, UK Change. As a word, it generally either fills us with dread